Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioCardia, Inc. (NASDAQ: BCDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary disease, BioCardia uses these filings to report on financial results, governance matters, clinical and regulatory milestones, and capital markets activity.
Here you can review current reports on Form 8-K, which BioCardia uses to announce material events such as quarterly financial results, progress in its CardiAMP and CardiALLO clinical programs, enrollment updates in the CardiAMP HF II Phase 3 trial, consultations with Japan’s PMDA, leadership and board changes, and notices related to Nasdaq listing compliance. These filings often incorporate or reference press releases that detail developments in the company’s investigational therapies and enabling technologies like the Helix delivery system and Morph vascular navigation platform.
Investors can also consult proxy materials such as the definitive proxy statement on Schedule DEF 14A, which outlines proposals for director elections, amendments to the equity incentive plan, auditor ratification, and advisory votes on executive compensation, as well as information on board structure and corporate governance. Periodic reports on Forms 10-K and 10-Q, referenced in company communications, provide broader context on risk factors, financial condition, and the status of clinical programs.
Stock Titan enhances these documents with AI-powered summaries that highlight key points, helping readers quickly understand the significance of lengthy filings, including complex sections on clinical trial status, equity financings, and listing compliance. Real-time updates from EDGAR, along with structured access to items such as results of operations, other events, and shareholder meeting notices, make this BCDA filings page a focused resource for analyzing BioCardia’s regulatory and corporate disclosures.
BioCardia, Inc. filed an 8-K reporting that it has completed a Pre-Submission to the U.S. Food and Drug Administration under the Q-Submission program for approval of its Helix transendocardial delivery catheter for intramyocardial therapeutic and diagnostic agent delivery.
The Pre-Submission is supported by data from fifteen well-controlled clinical trials in three primary cardiac indications and is made under the CardiAMP Cell Therapy System FDA Breakthrough Designation. BioCardia seeks to align with FDA on the regulatory pathway and timing for approval within the next 45 days, after which an application for market clearance could follow.
The company states this process should support Helix becoming the first approved transendocardial delivery catheter system in the United States and may streamline future approvals of its CardiAMP and CardiALLO cell therapies and potential partners’ cardiovascular cell, gene, and protein programs.
BioCardia, Inc. President and CEO Peter Altman, who is also a director, reported buying additional common stock of the company. On 02/04/2026, he purchased 5,000 shares of BioCardia common stock at a price of $1.13 per share.
Following this transaction, Altman beneficially owned 273,866 shares of BioCardia common stock, held in direct ownership. The filing was made on a Form 4, which reports insider trades by company officers and directors.
BioCardia, Inc. reported that echocardiography data from its CardiAMP Cell Therapy program for the treatment of heart failure has been accepted as a Late Breaking Clinical Trial oral presentation at the Technology and Heart Failure Therapeutics (THT) Meeting. This conference is scheduled for March 2-4, 2026, in Boston, Massachusetts.
The company furnished a press release as an exhibit, which provides additional detail on the CardiAMP heart failure data to be discussed at the meeting. This disclosure is characterized as an informational event rather than a financial or transactional update.
BioCardia, Inc. insider activity: President and CEO Peter Altman reported open‑market purchases of the company’s common stock on two consecutive days in January. On January 20, 2026, he bought 600 shares at a weighted average price of $1.32 per share, in multiple trades executed between $1.31 and $1.33. On January 21, 2026, he purchased an additional 300 shares at a weighted average price of $1.34 per share, in trades executed between $1.34 and $1.35. Following these transactions, he directly owned 268,866 shares of BioCardia common stock.
BioCardia, Inc. filed a registration statement to register 424,509 shares of its common stock for issuance under its Amended and Restated 2016 Equity Incentive Plan. These shares became available for grant and issuance on December 2, 2025, after stockholders approved the Restated Plan at the 2025 Annual Meeting of Stockholders.
The Restated Plan also provides for an automatic annual increase on the first day of each fiscal year equal to 4.0% of the company’s outstanding common stock on the preceding day. The filing also describes standard Delaware law and company provisions for indemnifying directors and officers, and it lists the exhibits related to the plan, opinion of counsel, and consents.
BioCardia, Inc.'s president, CEO and director reported open-market purchases of the company’s common stock. On December 16, 2025, the reporting person bought 200 shares of BioCardia common stock at a weighted average price of $1.37 per share, executed in multiple trades between $1.28 and $1.46 per share. On December 17, 2025, they bought an additional 900 shares at a weighted average price of $1.30 per share, with individual trade prices ranging from $1.23 to $1.38 per share. After these transactions, the reporting person beneficially owned 267,966 shares of BioCardia common stock, held directly.
BioCardia, Inc. reported that Japan’s Pharmaceutical and Medical Device Agency has agreed to let the company move its CardiAMP Cell Therapy for the treatment of heart failure with reduced ejection fraction into a formal clinical consultation process. This follows completion of a third preliminary clinical consultation with the agency. If, in that formal consultation, the PMDA concludes that the available data provide sufficient evidence of safety and efficacy, BioCardia would be able to file for regulatory approval in Japan for this cell therapy.
BioCardia, Inc. Senior Vice President, Devices reported equity compensation activity. On December 8, 2025, the executive acquired 38,078 restricted stock units (RSUs), each equal to one share of common stock awarded as compensation in lieu of cash, with 100% of the RSUs vesting on that date. To cover income tax withholding for the vested RSUs, 15,172 shares were withheld by BioCardia, which is not a sale by the executive. After these transactions, the executive beneficially owned 31,874 shares of common stock. The filing also reports a grant of a stock option for 20,000 shares at an exercise price of $1.37 per share, expiring on December 8, 2035, vesting as to 1/48th of the shares starting January 8, 2026 and monthly thereafter, contingent on continued service.
BioCardia, Inc. director reports new stock option grant
A BioCardia, Inc. director filed a Form 4 reporting the grant of a stock option on 12/08/2025. The option gives the right to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. According to the filing, all of these shares are scheduled to vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues as a service provider through that date.
After this grant, the reporting person beneficially owns 15,313 derivative securities, held directly. The option is shown with an expiration date of 12/08/2035, providing a long-term window during which the director may choose to exercise the option once vested.
BioCardia, Inc. reported an insider equity award to one of its directors. On 12/08/2025, the director received a stock option to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. The option vests and becomes fully exercisable on the one-year anniversary of the grant date, so long as the director continues as a service provider through that date, and it expires on 12/08/2035. Following this grant, the director beneficially owns 15,729 derivative securities, held directly.